Distributor inventory | Capsule
Rabeprazole (as enteric-coated) 20 mg + Levosulpiride (sustained/controlled release) 75 mg capsule
Gastroesophageal reflux disease (GERD), heartburn/acid reflux, erosive esophagitis, gastritis and dyspepsia associated with delayed gastric emptying (functional dyspepsia)
Rabeprazole is a proton pump inhibitor that irreversibly blocks the H+/K+ ATPase in stomach parietal cells, reducing acid production. Levosulpiride is a prokinetic (dopamine D2 antagonist) that enhances gastric motility and improves gastric emptying, helping relieve reflux and bloating.
Capsule for oral use. Typically taken once daily 30 minutes before food (preferably before breakfast) or as directed by the physician. Swallow whole; do not crush or chew the capsule/modified-release pellets.
Common side effects of RABEPACE LS CAP may include:
Use only on medical advice. Long-term PPI use may increase risk of vitamin B12 deficiency, low magnesium, fractures, and gut infections (e.g., C. difficile). Seek care if alarm symptoms occur (weight loss, vomiting blood, black stools, difficulty swallowing). Levosulpiride can cause extrapyramidal symptoms, drowsiness, and raised prolactin; use caution in Parkinson’s disease, epilepsy, and patients with history of movement disorders. Use caution in severe liver disease; dose adjustment/monitoring may be needed in kidney impairment (levosulpiride is renally cleared). May affect ability to drive if dizziness/somnolence occurs.
